Credit: Ernesto del Aguila III, National Human Genome Research Institute, NIH
A pair of papers published in Nature Medicine have caused a stir about CRISPR-edited cells lacking a well-known tumor suppressor gene. STAT is doing an online chat next week to follow up the news. In the meantime, this is a sample of how the CRISPR community is commenting the story. Continue reading
Up and down, following the excitement for the latest scientific exploit or frustration for disappointing results. CRISPR is young but already knows how volatile is the market. “Preprint wipes millions off CRISPR companies’ stocks,” cries the March issue of Nature Biotechnology. Continue reading
The Swiss army knife is still the best analogy to describe what CRISPR can do, according to STAT’s top-ten, and we can’t disagree. But please take a look at this revised picture from Nature Reviews Genetics. CRISPR has learned new tricks; it’s much more than a pair of scissors by now.